MacroEcon / Shutterstock.com
27 June 2024NewsAmericasLiz Hockley

Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic

Judges considered Hikma’s label and marketing material when overturning lower court’s decision | Court said Amarin had stated plausible claim for induced infringement of patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
23 March 2023   Hikma label and public statements encouraged infringement, Amarin says | Delaware District Court had dismissed claims label was ‘not skinny enough’.
Americas
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.